Status: Recruiting
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.
Participants needed: 87
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: LISCure BiosciencesUpdated: Oct 24, 2025Locations: 7
Eligibility criteria
Age: 18 to 75 years [+7]
Treatment with any investigational agents within 3 months or 5 half-lives, which... [+19]